This module provides general principles for assigning additional monitoring status to medicinal products and on the communication and transparency aspects. It also describes the operation of the European Union network regarding the supervision of additional monitoring status, the communication strategy and the impact on pharmacovigilance activities.
Go to Source

This entry was posted on Wednesday, June 27th, 2012 at 12:30 pm and is filed under European Medicines Agency. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.